BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oppermann M, Manuelian T, Józsi M, Brandt E, Jokiranta TS, Heinen S, Meri S, Skerka C, Götze O, Zipfel PF. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006;144:342-52. [PMID: 16634809 DOI: 10.1111/j.1365-2249.2006.03071.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 118] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Reuter M, Caswell CC, Lukomski S, Zipfel PF. Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels. J Biol Chem 2010;285:38473-85. [PMID: 20855886 DOI: 10.1074/jbc.M110.143727] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
2 Skerka C, Zipfel PF. Complement factor H related proteins in immune diseases. Vaccine 2008;26:I9-I14. [DOI: 10.1016/j.vaccine.2008.11.021] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
3 Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol 2006;177:6308-16. [PMID: 17056561 DOI: 10.4049/jimmunol.177.9.6308] [Cited by in Crossref: 115] [Cited by in F6Publishing: 112] [Article Influence: 7.2] [Reference Citation Analysis]
4 Bykowski T, Woodman ME, Cooley AE, Brissette CA, Brade V, Wallich R, Kraiczy P, Stevenson B. Coordinated expression of Borrelia burgdorferi complement regulator-acquiring surface proteins during the Lyme disease spirochete's mammal-tick infection cycle. Infect Immun 2007;75:4227-36. [PMID: 17562769 DOI: 10.1128/IAI.00604-07] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
5 Park PJ, Shukla D. Role of heparan sulfate in ocular diseases. Exp Eye Res 2013;110:1-9. [PMID: 23410824 DOI: 10.1016/j.exer.2013.01.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
6 Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3:e41. [PMID: 17367211 DOI: 10.1371/journal.pgen.0030041] [Cited by in Crossref: 233] [Cited by in F6Publishing: 221] [Article Influence: 15.5] [Reference Citation Analysis]
7 Götting C, Hendig D, Zarbock R, Szliska C, Kleesiek K. Complement factor H variant p.Y402H in pseudoxanthoma elasticum patients. Genet Test 2008;12:431-6. [PMID: 18627285 DOI: 10.1089/gte.2008.0026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Dopler A, Guntau L, Harder MJ, Palmer A, Höchsmann B, Schrezenmeier H, Simmet T, Huber-lang M, Schmidt CQ. Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1. J I 2019;202:2082-94. [DOI: 10.4049/jimmunol.1801545] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
9 Okemefuna AI, Nan R, Gor J, Perkins SJ. Electrostatic interactions contribute to the folded-back conformation of wild type human factor H. J Mol Biol 2009;391:98-118. [PMID: 19505476 DOI: 10.1016/j.jmb.2009.06.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
10 Strobel S, Abarrategui-garrido C, Fariza-requejo E, Seeberger H, Sánchez-corral P, Józsi M. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney International 2011;80:397-404. [DOI: 10.1038/ki.2011.152] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
11 Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. J Am Soc Nephrol 2018;29:1141-53. [PMID: 29335241 DOI: 10.1681/ASN.2017070738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
12 Schmidt CQ, Herbert AP, Hocking HG, Uhrín D, Barlow PN. Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol. 2008;151:14-24. [PMID: 18081691 DOI: 10.1111/j.1365-2249.2007.03553.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.2] [Reference Citation Analysis]
13 Siegel C, Hallström T, Skerka C, Eberhardt H, Uzonyi B, Beckhaus T, Karas M, Wallich R, Stevenson B, Zipfel PF, Kraiczy P. Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi. PLoS One 2010;5:e13519. [PMID: 20975954 DOI: 10.1371/journal.pone.0013519] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
14 Behnsen J, Hartmann A, Schmaler J, Gehrke A, Brakhage AA, Zipfel PF. The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infect Immun 2008;76:820-7. [PMID: 18039838 DOI: 10.1128/IAI.01037-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
15 Leffler J, Herbert AP, Norström E, Schmidt CQ, Barlow PN, Blom AM, Martin M. Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. J Biol Chem. 2010;285:3766-3776. [PMID: 19951950 DOI: 10.1074/jbc.m109.045427] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
16 Bhattacharjee A, Reuter S, Trojnár E, Kolodziejczyk R, Seeberger H, Hyvärinen S, Uzonyi B, Szilágyi Á, Prohászka Z, Goldman A, Józsi M, Jokiranta TS. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 2015;290:9500-10. [PMID: 25659429 DOI: 10.1074/jbc.M114.630871] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
17 Puri TS, Quigg RJ. The Many Effects of Complement C3- and C5-Binding Proteins in Renal Injury. Seminars in Nephrology 2007;27:321-37. [DOI: 10.1016/j.semnephrol.2007.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
18 Scholl HPN, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, Weber BHF. Genetics of Age-Related Macular Degeneration: Update. In: Holz FG, Spaide RF, editors. Medical Retina. Berlin: Springer Berlin Heidelberg; 2007. pp. 35-52. [DOI: 10.1007/978-3-540-33672-3_3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Nozal P, Bernabéu-herrero ME, Uzonyi B, Szilágyi Á, Hyvärinen S, Prohászka Z, Jokiranta TS, Sánchez-corral P, López-trascasa M, Józsi M. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Molecular Immunology 2016;70:47-55. [DOI: 10.1016/j.molimm.2015.12.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
20 Stone BL, Brissette CA. Host Immune Evasion by Lyme and Relapsing Fever Borreliae: Findings to Lead Future Studies for Borrelia miyamotoi. Front Immunol 2017;8:12. [PMID: 28154563 DOI: 10.3389/fimmu.2017.00012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
22 Merle DA, Provenzano F, Jarboui MA, Kilger E, Clark SJ, Deleidi M, Armento A, Ueffing M. mTOR Inhibition via Rapamycin Treatment Partially Reverts the Deficit in Energy Metabolism Caused by FH Loss in RPE Cells. Antioxidants (Basel) 2021;10:1944. [PMID: 34943047 DOI: 10.3390/antiox10121944] [Reference Citation Analysis]
23 Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol 2013;190:5712-21. [PMID: 23616575 DOI: 10.4049/jimmunol.1203548] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 9.7] [Reference Citation Analysis]
24 Simon N, Lasonder E, Scheuermayer M, Kuehn A, Tews S, Fischer R, Zipfel P, Skerka C, Pradel G. Malaria Parasites Co-opt Human Factor H to Prevent Complement-Mediated Lysis in the Mosquito Midgut. Cell Host & Microbe 2013;13:29-41. [DOI: 10.1016/j.chom.2012.11.013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
25 Mark L, Spiller OB, Villoutreix BO, Blom AM. Kaposi's sarcoma-associated herpes virus complement control protein: KCP--complement inhibition and more. Mol Immunol 2007;44:11-22. [PMID: 16905191 DOI: 10.1016/j.molimm.2006.06.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
26 Uzonyi B, Szabó Z, Trojnár E, Hyvärinen S, Uray K, Nielsen HH, Erdei A, Jokiranta TS, Prohászka Z, Illes Z, Józsi M. Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. Front Immunol 2021;12:660382. [PMID: 33986750 DOI: 10.3389/fimmu.2021.660382] [Reference Citation Analysis]
27 Cruz-gonzález F, Lorenzo-pérez R, Cañete-campos C, Hernández-galilea E, González-sarmiento R. Influencia de haplotipos de polimorfismos de CFH, HTRA1 y ARMS2 en la aparición de degeneración macular asociada a la edad. Archivos de la Sociedad Española de Oftalmología 2013;88:3-10. [DOI: 10.1016/j.oftal.2012.04.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Agarwal V, Asmat TM, Luo S, Jensch I, Zipfel PF, Hammerschmidt S. Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells. J Biol Chem 2010;285:23486-95. [PMID: 20504767 DOI: 10.1074/jbc.M110.142703] [Cited by in Crossref: 63] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
29 Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration. J Immunol 2014;193:4962-70. [PMID: 25305316 DOI: 10.4049/jimmunol.1401613] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
30 Medjeral-Thomas N, Pickering MC. The complement factor H-related proteins. Immunol Rev. 2016;274:191-201. [PMID: 27782332 DOI: 10.1111/imr.12477] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
31 Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol. 2015;6:262. [PMID: 26082779 DOI: 10.3389/fimmu.2015.00262] [Cited by in Crossref: 521] [Cited by in F6Publishing: 553] [Article Influence: 74.4] [Reference Citation Analysis]
32 Biggs RM, Makou E, Lauder S, Herbert AP, Barlow PN, Katti SK. A novel full-length recombinant human complement factor H (CFH; GEM103) for the treatment of age-related macular degeneration shows similar in vitro functional activity to native CFH. Current Eye Research. [DOI: 10.1080/02713683.2022.2053725] [Reference Citation Analysis]
33 Buelli S, Abbate M, Morigi M, Moioli D, Zanchi C, Noris M, Zoja C, Pusey CD, Zipfel PF, Remuzzi G. Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney Int. 2009;75:1050-1059. [PMID: 19242507 DOI: 10.1038/ki.2009.8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
34 Irmscher S, Brix SR, Zipfel SLH, Halder LD, Mutlutürk S, Wulf S, Girdauskas E, Reichenspurner H, Stahl RAK, Jungnickel B, Wiech T, Zipfel PF, Skerka C. Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies. Nat Commun 2019;10:2961. [PMID: 31273197 DOI: 10.1038/s41467-019-10766-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
35 Nan R, Gor J, Perkins SJ. Implications of the Progressive Self-association of Wild-type Human Factor H for Complement Regulation and Disease. Journal of Molecular Biology 2008;375:891-900. [DOI: 10.1016/j.jmb.2007.11.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
36 Gurjar BS, Manikanta Sriharsha T, Bhasym A, Prabhu S, Puraswani M, Khandelwal P, Saini H, Saini S, Verma AK, Chatterjee P, Guchhait P, Bal V, George A, Rath S, Sahu A, Sharma A, Hari P, Sinha A, Bagga A. Characterization of genetic predisposition and autoantibody profile in atypical haemolytic-uraemic syndrome. Immunology 2018. [PMID: 29485195 DOI: 10.1111/imm.12916] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
37 Alexander JJ, Quigg RJ. The simple design of complement factor H: Looks can be deceiving. Molecular Immunology 2007;44:123-32. [DOI: 10.1016/j.molimm.2006.07.287] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
38 Wymann S, Dai Y, Nair AG, Cao H, Powers GA, Schnell A, Martin-Roussety G, Leong D, Simmonds J, Lieu KG, de Souza MJ, Mischnik M, Taylor S, Ow SY, Spycher M, Butcher RE, Pearse M, Zuercher AW, Baz Morelli A, Panousis C, Wilson MJ, Rowe T, Hardy MP. A novel soluble complement receptor 1 fragment with enhanced therapeutic potential. J Biol Chem 2021;296:100200. [PMID: 33334893 DOI: 10.1074/jbc.RA120.016127] [Reference Citation Analysis]
39 Schmidt CQ, Hipgrave Ederveen AL, Harder MJ, Wuhrer M, Stehle T, Blaum BS. Biophysical analysis of sialic acid recognition by the complement regulator Factor H. Glycobiology 2018;28:765-73. [PMID: 29982679 DOI: 10.1093/glycob/cwy061] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
40 Ferluga J, Kouser L, Murugaiah V, Sim RB, Kishore U. Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders. Mol Immunol 2017;84:84-106. [PMID: 28216098 DOI: 10.1016/j.molimm.2017.01.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
41 Schmidt CQ, Herbert AP, Mertens HD, Guariento M, Soares DC, Uhrin D, Rowe AJ, Svergun DI, Barlow PN. The central portion of factor H (modules 10-15) is compact and contains a structurally deviant CCP module. J Mol Biol 2010;395:105-22. [PMID: 19835885 DOI: 10.1016/j.jmb.2009.10.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
42 Borras C, Canonica J, Jorieux S, Abache T, El Sanharawi M, Klein C, Delaunay K, Jonet L, Salvodelli M, Naud MC, Arsenijevic Y, Shalabi A, Souchaud L, Behar-Cohen F, Dinet V. CFH exerts anti-oxidant effects on retinal pigment epithelial cells independently from protecting against membrane attack complex. Sci Rep 2019;9:13873. [PMID: 31554875 DOI: 10.1038/s41598-019-50420-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
43 Rudnick RB, Chen Q, Stea ED, Hartmann A, Papac-Milicevic N, Person F, Wiesener M, Binder CJ, Wiech T, Skerka C, Zipfel PF. FHR5 Binds to Laminins, Uses Separate C3b and Surface-Binding Sites, and Activates Complement on Malondialdehyde-Acetaldehyde Surfaces. J Immunol 2018;200:2280-90. [PMID: 29483359 DOI: 10.4049/jimmunol.1701641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
44 Kopp A, Hebecker M, Svobodová E, Józsi M. Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules 2012;2:46-75. [PMID: 24970127 DOI: 10.3390/biom2010046] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 7.2] [Reference Citation Analysis]
45 Perkins SJ, Nan R, Li K, Khan S, Miller A. Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. Immunobiology 2012;217:281-97. [PMID: 22137027 DOI: 10.1016/j.imbio.2011.10.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
46 Mihlan M, Stippa S, Józsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 2009;16:1630-40. [PMID: 19680263 DOI: 10.1038/cdd.2009.103] [Cited by in Crossref: 95] [Cited by in F6Publishing: 96] [Article Influence: 7.3] [Reference Citation Analysis]
47 Dekkers G, Brouwer MC, Jeremiasse J, Kamp A, Biggs RM, van Mierlo G, Lauder S, Katti S, Kuijpers TW, Rispens T, Jongerius I. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants. J Immunol 2020;205:1778-86. [PMID: 32848031 DOI: 10.4049/jimmunol.2000368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Cugno M, Berra S, Depetri F, Tedeschi S, Griffini S, Grovetti E, Caccia S, Cresseri D, Messa P, Testa S, Giglio F, Peyvandi F, Ardissino G. IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2021;32:1227-35. [PMID: 33712527 DOI: 10.1681/ASN.2020081224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Harder MJ, Anliker M, Höchsmann B, Simmet T, Huber-Lang M, Schrezenmeier H, Ricklin D, Lambris JD, Barlow PN, Schmidt CQ. Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. J Immunol 2016;196:866-76. [PMID: 26643478 DOI: 10.4049/jimmunol.1501919] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
50 Makou E, Bailey RG, Johnston H, Parkin JD, Hulme AN, Hähner G, Barlow PN. Combining SPR with atomic-force microscopy enables single-molecule insights into activation and suppression of the complement cascade. J Biol Chem 2019;294:20148-63. [PMID: 31719147 DOI: 10.1074/jbc.RA119.010913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Rossmann E, Kraiczy P, Herzberger P, Skerka C, Kirschfink M, Simon MM, Zipfel PF, Wallich R. Dual binding specificity of a Borrelia hermsii-associated complement regulator-acquiring surface protein for factor H and plasminogen discloses a putative virulence factor of relapsing fever spirochetes. J Immunol 2007;178:7292-301. [PMID: 17513779 DOI: 10.4049/jimmunol.178.11.7292] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.1] [Reference Citation Analysis]
52 Hammerschmidt S, Agarwal V, Kunert A, Haelbich S, Skerka C, Zipfel PF. The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol 2007;178:5848-58. [PMID: 17442969 DOI: 10.4049/jimmunol.178.9.5848] [Cited by in Crossref: 103] [Cited by in F6Publishing: 104] [Article Influence: 6.9] [Reference Citation Analysis]
53 Herbert AP, Deakin JA, Schmidt CQ, Blaum BS, Egan C, Ferreira VP, Pangburn MK, Lyon M, Uhrín D, Barlow PN. Structure Shows That a Glycosaminoglycan and Protein Recognition Site in Factor H Is Perturbed by Age-related Macular Degeneration-linked Single Nucleotide Polymorphism. Journal of Biological Chemistry 2007;282:18960-8. [DOI: 10.1074/jbc.m609636200] [Cited by in Crossref: 88] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
54 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
55 Clark SJ, Bishop PN. Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration. J Clin Med 2015;4:18-31. [PMID: 25729613 DOI: 10.3390/jcm4010018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
56 Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, Day AJ. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem 2010;285:30192-202. [PMID: 20660596 DOI: 10.1074/jbc.M110.103986] [Cited by in Crossref: 125] [Cited by in F6Publishing: 92] [Article Influence: 10.4] [Reference Citation Analysis]
57 Castiblanco-valencia MM, Fraga TR, Silva LBD, Monaris D, Abreu PAE, Strobel S, Józsi M, Isaac L, Barbosa AS. Leptospiral Immunoglobulin-like Proteins Interact With Human Complement Regulators Factor H, FHL-1, FHR-1, and C4BP. The Journal of Infectious Diseases 2012;205:995-1004. [DOI: 10.1093/infdis/jir875] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 9.9] [Reference Citation Analysis]
58 Blom AM, Volokhina EB, Fransson V, Strömberg P, Berghard L, Viktorelius M, Mollnes TE, López-Trascasa M, van den Heuvel LP, Goodship TH, Marchbank KJ, Okroj M. A novel method for direct measurement of complement convertases activity in human serum. Clin Exp Immunol 2014;178:142-53. [PMID: 24853370 DOI: 10.1111/cei.12388] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
59 Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry. 2013;52:3949-3962. [PMID: 23701234 DOI: 10.1021/bi4003452] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 9.3] [Reference Citation Analysis]
60 Józsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol 2007;44:2697-706. [PMID: 17208302 DOI: 10.1016/j.molimm.2006.12.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 4.9] [Reference Citation Analysis]
61 Skerka C, Józsi M. Role of complement and Factor H in hemolytic uremic syndrome. In: Zipfel PF, editor. Complement and Kidney Disease. Basel: Birkhäuser-Verlag; 2006. pp. 85-109. [DOI: 10.1007/3-7643-7428-4_6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Hallström T, Zipfel PF, Blom AM, Lauer N, Forsgren A, Riesbeck K. Haemophilus influenzae Interacts with the Human Complement Inhibitor Factor H. J Immunol 2008;181:537-45. [DOI: 10.4049/jimmunol.181.1.537] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
63 Makou E, Mertens HD, Maciejewski M, Soares DC, Matis I, Schmidt CQ, Herbert AP, Svergun DI, Barlow PN. Solution structure of CCP modules 10-12 illuminates functional architecture of the complement regulator, factor H. J Mol Biol 2012;424:295-312. [PMID: 23017427 DOI: 10.1016/j.jmb.2012.09.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
64 Castelletti F, Donadelli R, Banterla F, Hildebrandt F, Zipfel PF, Bresin E, Otto E, Skerka C, Renieri A, Todeschini M, Caprioli J, Caruso RM, Artuso R, Remuzzi G, Noris M. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A 2008;105:2538-43. [PMID: 18268355 DOI: 10.1073/pnas.0707730105] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
65 Cantsilieris S, Nelson BJ, Huddleston J, Baker C, Harshman L, Penewit K, Munson KM, Sorensen M, Welch AE, Dang V, Grassmann F, Richardson AJ, Guymer RH, Graves-Lindsay TA, Wilson RK, Weber BHF, Baird PN, Allikmets R, Eichler EE. Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (CFH) gene family. Proc Natl Acad Sci U S A 2018;115:E4433-42. [PMID: 29686068 DOI: 10.1073/pnas.1717600115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
66 Mannes M, Dopler A, Huber-Lang M, Schmidt CQ. Tuning the Functionality by Splicing: Factor H and Its Alternative Splice Variant FHL-1 Share a Gene but Not All Functions. Front Immunol 2020;11:596415. [PMID: 33178228 DOI: 10.3389/fimmu.2020.596415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
67 Zipfel PF, Mache C, Müller D, Licht C, Wigger M, Skerka C; for the European DEAP-HUS Study Group. DEAP-HUS: Deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol 2010;25:2009-19. [DOI: 10.1007/s00467-010-1446-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
68 Poolpol K, Orth-Höller D, Speth C, Zipfel PF, Skerka C, de Córdoba SR, Brockmeyer J, Bielaszewska M, Würzner R. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 2014;58:77-84. [PMID: 24317278 DOI: 10.1016/j.molimm.2013.11.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
69 Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008;181:8068-76. [PMID: 19017999 DOI: 10.4049/jimmunol.181.11.8068] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 6.6] [Reference Citation Analysis]
70 De Groot PG, Meijers JCM. β2-Glycoprotein I: evolution, structure and function: β2-Glycoprotein I. Journal of Thrombosis and Haemostasis 2011;9:1275-84. [DOI: 10.1111/j.1538-7836.2011.04327.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 10.9] [Reference Citation Analysis]
71 Morgan HP, Mertens HD, Guariento M, Schmidt CQ, Soares DC, Svergun DI, Herbert AP, Barlow PN, Hannan JP. Structural analysis of the C-terminal region (modules 18-20) of complement regulator factor H (FH). PLoS One 2012;7:e32187. [PMID: 22389686 DOI: 10.1371/journal.pone.0032187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
72 Rosa TF, Flammersfeld A, Ngwa CJ, Kiesow M, Fischer R, Zipfel PF, Skerka C, Pradel G. The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complement. Cell Microbiol 2016;18:573-90. [PMID: 26457721 DOI: 10.1111/cmi.12535] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
73 Hallström T, Mörgelin M, Barthel D, Raguse M, Kunert A, Hoffmann R, Skerka C, Zipfel PF. Dihydrolipoamide Dehydrogenase of Pseudomonas aeruginosa Is a Surface-Exposed Immune Evasion Protein That Binds Three Members of the Factor H Family and Plasminogen. J I 2012;189:4939-50. [DOI: 10.4049/jimmunol.1200386] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
74 Heinen S, Józsi M, Hartmann A, Noris M, Remuzzi G, Skerka C, Zipfel PF. Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells. JASN 2007;18:506-14. [DOI: 10.1681/asn.2006091069] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
75 Okemefuna AI, Li K, Nan R, Ormsby RJ, Sadlon T, Gordon DL, Perkins SJ. Multimeric interactions between complement factor H and its C3d ligand provide new insight on complement regulation. J Mol Biol 2009;391:119-35. [PMID: 19505474 DOI: 10.1016/j.jmb.2009.06.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
76 Yang Y, Back CR, Gräwert MA, Wahid AA, Denton H, Kildani R, Paulin J, Wörner K, Kaiser W, Svergun DI, Sartbaeva A, Watts AG, Marchbank KJ, van den Elsen JMH. Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant. Front Immunol 2018;9:3139. [PMID: 30687332 DOI: 10.3389/fimmu.2018.03139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
77 Ruiz-Molina N, Parsons J, Müller M, Hoernstein SNW, Bohlender LL, Pumple S, Zipfel PF, Häffner K, Reski R, Decker EL. A synthetic protein as efficient multitarget regulator against complement over-activation. Commun Biol 2022;5:152. [PMID: 35194132 DOI: 10.1038/s42003-022-03094-5] [Reference Citation Analysis]
78 Giannakopoulos B, Mirarabshahi P, Krilis SA. New Insights into the Biology and Pathobiology of Beta2-Glycoprotein I. Curr Rheumatol Rep 2011;13:90-5. [DOI: 10.1007/s11926-010-0151-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
79 Langford-Smith A, Day AJ, Bishop PN, Clark SJ. Complementing the Sugar Code: Role of GAGs and Sialic Acid in Complement Regulation. Front Immunol 2015;6:25. [PMID: 25699044 DOI: 10.3389/fimmu.2015.00025] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
80 Hörl S, Banki Z, Huber G, Ejaz A, Müllauer B, Willenbacher E, Steurer M, Stoiber H. Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica 2013;98:1939-47. [PMID: 23850806 DOI: 10.3324/haematol.2013.089615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
81 Schmidt CQ, Harder MJ, Nichols EM, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi ÁI, Uzonyi B, Pappworth IY, Ricklin D, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 2016;221:503-11. [PMID: 26792457 DOI: 10.1016/j.imbio.2015.12.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
82 Park S, Lee YJ, Kim YW, Ko J, Park JH, Kim IH, Kim HJ, Oh D, Park BS. Atypical Hemolytic Uremic Syndrome (p.Gly1110Ala) with Autoimmune Disease. Am J Case Rep 2020;21:e922567. [PMID: 32361709 DOI: 10.12659/AJCR.922567] [Reference Citation Analysis]
83 Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem. 2010;285:1053-1065. [PMID: 19850925 DOI: 10.1074/jbc.m109.044529] [Cited by in Crossref: 90] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
84 Kunert A, Losse J, Gruszin C, Hühn M, Kaendler K, Mikkat S, Volke D, Hoffmann R, Jokiranta TS, Seeberger H, Moellmann U, Hellwage J, Zipfel PF. Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol 2007;179:2979-88. [PMID: 17709513 DOI: 10.4049/jimmunol.179.5.2979] [Cited by in Crossref: 155] [Cited by in F6Publishing: 163] [Article Influence: 10.3] [Reference Citation Analysis]
85 Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson B, Nilsson Ekdahl K, Ricklin D, Lambris JD. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol 2011;186:4269-77. [PMID: 21339361 DOI: 10.4049/jimmunol.1003802] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
86 Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Józsi M. Autoimmune forms of thrombotic micorangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Molecular Immunology 2009;46:2801-7. [DOI: 10.1016/j.molimm.2009.05.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
87 Józsi M, Schneider AE, Kárpáti É, Sándor N. Complement factor H family proteins in their non-canonical role as modulators of cellular functions. Seminars in Cell & Developmental Biology 2019;85:122-31. [DOI: 10.1016/j.semcdb.2017.12.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
88 Smolag KI, Mueni CM, Leandersson K, Jirström K, Hagerling C, Mörgelin M, Barlow PN, Martin M, Blom AM. Complement inhibitor factor H expressed by breast cancer cells differentiates CD14+ human monocytes into immunosuppressive macrophages. Oncoimmunology 2020;9:1731135. [PMID: 32923173 DOI: 10.1080/2162402X.2020.1731135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Bhasym A, Gurjar BS, Prabhu S, Puraswani M, Khandelwal P, Saini H, Saini S, Chatterjee P, Bal V, George A, Coshic P, Patidar G, Hari P, Sinha A, Bagga A, Rath S, Guchhait P. Altered Peripheral Blood Leucocyte Phenotype and Responses in Healthy Individuals with Homozygous Deletion of FHR1 and FHR3 Genes. J Clin Immunol 2019;39:336-45. [DOI: 10.1007/s10875-019-00619-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
90 de Groot PG, de Laat B, Rand J, Vlachoyiannopoulos PG, El-assaad F, Krilis SA, Giannakopoulos B. Natural Proteins Involved in Antiphospholipid Syndrome. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome. Cham: Springer International Publishing; 2017. pp. 15-27. [DOI: 10.1007/978-3-319-55442-6_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 Kárpáti É, Papp A, Schneider AE, Hajnal D, Cserhalmi M, Csincsi ÁI, Uzonyi B, Józsi M. Interaction of the Factor H Family Proteins FHR-1 and FHR-5 With DNA and Dead Cells: Implications for the Regulation of Complement Activation and Opsonization. Front Immunol 2020;11:1297. [PMID: 32765490 DOI: 10.3389/fimmu.2020.01297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
92 Heinen S, Hartmann A, Lauer N, Wiehl U, Dahse HM, Schirmer S, Gropp K, Enghardt T, Wallich R, Hälbich S, Mihlan M, Schlötzer-Schrehardt U, Zipfel PF, Skerka C. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009;114:2439-47. [PMID: 19528535 DOI: 10.1182/blood-2009-02-205641] [Cited by in Crossref: 190] [Cited by in F6Publishing: 181] [Article Influence: 14.6] [Reference Citation Analysis]
93 Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, Lyon M, Uhrín D, Barlow PN. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol 2008;181:2610-9. [PMID: 18684951 DOI: 10.4049/jimmunol.181.4.2610] [Cited by in Crossref: 146] [Cited by in F6Publishing: 141] [Article Influence: 10.4] [Reference Citation Analysis]
94 Kelly U, Yu L, Kumar P, Ding JD, Jiang H, Hageman GS, Arshavsky VY, Frank MM, Hauser MA, Rickman CB. Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. J Immunol 2010;185:5486-94. [PMID: 20876352 DOI: 10.4049/jimmunol.0903596] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
95 van Burgel ND, Kraiczy P, Schuijt TJ, Zipfel PF, van Dam AP. Identification and functional characterisation of Complement Regulator Acquiring Surface Protein-1 of serum resistant Borrelia garinii OspA serotype 4. BMC Microbiol 2010;10:43. [PMID: 20146822 DOI: 10.1186/1471-2180-10-43] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
96 Baud A, Gonnet F, Salard I, Le Mignon M, Giuliani A, Mercère P, Sclavi B, Daniel R. Probing the solution structure of Factor H using hydroxyl radical protein footprinting and cross-linking. Biochem J 2016;473:1805-19. [PMID: 27099340 DOI: 10.1042/BCJ20160225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
97 Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. Immunol Rev 2016;274:152-71. [PMID: 27782321 DOI: 10.1111/imr.12475] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 19.8] [Reference Citation Analysis]
98 Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007;110:1516-8. [PMID: 17495132 DOI: 10.1182/blood-2007-02-071472] [Cited by in Crossref: 169] [Cited by in F6Publishing: 161] [Article Influence: 11.3] [Reference Citation Analysis]
99 Nan R, Gor J, Lengyel I, Perkins SJ. Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease. J Mol Biol 2008;384:1341-52. [PMID: 18976665 DOI: 10.1016/j.jmb.2008.10.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
100 Hebecker M, Alba-Domínguez M, Roumenina LT, Reuter S, Hyvärinen S, Dragon-Durey MA, Jokiranta TS, Sánchez-Corral P, Józsi M. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013;191:912-21. [PMID: 23772024 DOI: 10.4049/jimmunol.1300269] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
101 Haapasalo K, Jarva H, Siljander T, Tewodros W, Vuopio-Varkila J, Jokiranta TS. Complement factor H allotype 402H is associated with increased C3b opsonization and phagocytosis of Streptococcus pyogenes. Mol Microbiol 2008;70:583-94. [PMID: 18627465 DOI: 10.1111/j.1365-2958.2008.06347.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
102 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
103 Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, Kavanagh D, Mertens HD, Svergun DI, Johansson CM. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol. 2011;18:463-470. [PMID: 21317894 DOI: 10.1038/nsmb.2018] [Cited by in Crossref: 171] [Cited by in F6Publishing: 162] [Article Influence: 15.5] [Reference Citation Analysis]
104 Csincsi ÁI, Szabó Z, Bánlaki Z, Uzonyi B, Cserhalmi M, Kárpáti É, Tortajada A, Caesar JJE, Prohászka Z, Jokiranta TS, Lea SM, Rodríguez de Córdoba S, Józsi M. FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation. J Immunol 2017;199:292-303. [PMID: 28533443 DOI: 10.4049/jimmunol.1600483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
105 Hörl S, Bánki Z, Huber G, Ejaz A, Windisch D, Muellauer B, Willenbacher E, Steurer M, Stoiber H. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 2013;27:2200-8. [PMID: 23760402 DOI: 10.1038/leu.2013.169] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
106 Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010;25:136-44. [PMID: 19666655 DOI: 10.1093/ndt/gfp388] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
107 Józsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol 2008;29:380-7. [PMID: 18602340 DOI: 10.1016/j.it.2008.04.008] [Cited by in Crossref: 177] [Cited by in F6Publishing: 170] [Article Influence: 12.6] [Reference Citation Analysis]
108 Poltermann S, Kunert A, von der Heide M, Eck R, Hartmann A, Zipfel PF. Gpm1p is a factor H-, FHL-1-, and plasminogen-binding surface protein of Candida albicans. J Biol Chem 2007;282:37537-44. [PMID: 17959597 DOI: 10.1074/jbc.M707280200] [Cited by in Crossref: 88] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
109 Kerr H, Wong E, Makou E, Yang Y, Marchbank K, Kavanagh D, Richards A, Herbert AP, Barlow PN. Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation. J Biol Chem 2017;292:13345-60. [PMID: 28637873 DOI: 10.1074/jbc.M117.795088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
110 Kopp A, Strobel S, Tortajada A, Rodríguez de Córdoba S, Sánchez-Corral P, Prohászka Z, López-Trascasa M, Józsi M. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J Immunol 2012;189:1858-67. [PMID: 22786770 DOI: 10.4049/jimmunol.1200357] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
111 Brissette CA, Cooley AE, Burns LH, Riley SP, Verma A, Woodman ME, Bykowski T, Stevenson B. Lyme borreliosis spirochete Erp proteins, their known host ligands, and potential roles in mammalian infection. Int J Med Microbiol 2008;298 Suppl 1:257-67. [PMID: 18248770 DOI: 10.1016/j.ijmm.2007.09.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
112 Nan R, Farabella I, Schumacher FF, Miller A, Gor J, Martin AC, Jones DT, Lengyel I, Perkins SJ. Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration. J Mol Biol 2011;408:714-35. [PMID: 21396937 DOI: 10.1016/j.jmb.2011.03.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
113 Halfinger B, Hammerer-Lercher A, Amplatz B, Sarg B, Kremser L, Lindner HH. Unraveling the Molecular Complexity of O-Glycosylated Endogenous (N-Terminal) pro-B-Type Natriuretic Peptide Forms in Blood Plasma of Patients with Severe Heart Failure. Clin Chem 2017;63:359-68. [PMID: 28062629 DOI: 10.1373/clinchem.2016.265397] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
114 Blom AM, Mark L, Spiller OB. Viral Heparin-Binding Complement Inhibitors – A Recurring Theme. In: Lambris JD, editor. Current Topics in Innate Immunity. New York: Springer; 2007. pp. 105-25. [DOI: 10.1007/978-0-387-71767-8_9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
115 Mortimer GM, Minchin RF. Cryptic epitopes and functional diversity in extracellular proteins. The International Journal of Biochemistry & Cell Biology 2016;81:112-20. [DOI: 10.1016/j.biocel.2016.10.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
116 Wang F, Yu F, Zhao M. A method of purifying intact complement factor H from human plasma. Protein Expression and Purification 2013;91:105-11. [DOI: 10.1016/j.pep.2013.07.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
117 Okemefuna AI, Gilbert HE, Griggs KM, Ormsby RJ, Gordon DL, Perkins SJ. The regulatory SCR-1/5 and cell surface-binding SCR-16/20 fragments of factor H reveal partially folded-back solution structures and different self-associative properties. J Mol Biol 2008;375:80-101. [PMID: 18005991 DOI: 10.1016/j.jmb.2007.09.026] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
118 Caswell CC, Han R, Hovis KM, Ciborowski P, Keene DR, Marconi RT, Lukomski S. The Scl1 protein of M6-type group A Streptococcus binds the human complement regulatory protein, factor H, and inhibits the alternative pathway of complement. Molecular Microbiology 2008;67:584-96. [DOI: 10.1111/j.1365-2958.2007.06067.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
119 Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. Br J Haematol 2020;189:182-6. [PMID: 31879952 DOI: 10.1111/bjh.16297] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
120 Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J 2015;34:2735-57. [PMID: 26489954 DOI: 10.15252/embj.201591881] [Cited by in Crossref: 165] [Cited by in F6Publishing: 149] [Article Influence: 23.6] [Reference Citation Analysis]
121 Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, Hallström T, Skerka C. β₂-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 2011;118:2774-83. [PMID: 21757614 DOI: 10.1182/blood-2011-02-339564] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
122 Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M. Extended haplotypes in the complement factor H ( CFH ) and CFH‐related ( CFHR ) family of genes protect against age‐related macular degeneration: Characterization, ethnic distribution and evolutionary implications. Annals of Medicine 2009;38:592-604. [DOI: 10.1080/07853890601097030] [Cited by in Crossref: 166] [Cited by in F6Publishing: 72] [Article Influence: 12.8] [Reference Citation Analysis]